The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
12/24/2009
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
RFA-CA-10-502
Opportunity Category:
Discretionary
Posted Date:
Dec 24, 2009
Creation Date:
Dec 24, 2009
Original Closing Date for Applications:
Mar 03, 2010
Current Closing Date for Applications:
Mar 03, 2010
Archive Date:
Apr 03, 2010
Funding Instrument Type:
Cooperative Agreement
Category of Funding Activity:
Education
Health
Category Explanation:
Expected Number of Awards:
Estimated Total Program Funding:
$4,680,000
Award Ceiling:
Award Floor:
CFDA Number(s):
93.393
--
Cancer Cause and Prevention Research
93.394
--
Cancer Detection and Diagnosis Research
93.395
--
Cancer Treatment Research
93.396
--
Cancer Biology Research
93.399
--
Cancer Control
Cost Sharing or Matching Requirement:
No
Eligible Applicants
Public and State controlled institutions of higher education
Additional Information on Eligibility:
Other Eligible Applicants include the following:
The eligibility to apply in response to this limited competition FOA is limited to the current AMC Group Chair recipient institution (U01CA121947).
Agency Name
National Institutes of Health
Description
Purpose. The purpose of this limited competition funding opportunity announcement (FOA) is to continue support of the research activities of AIDS Malignancy Consortium which are: 1) design, development, and evaluation of clinical interventions for the prevention and treatment of malignancies in patients with HIV infection; 2) development of more effective management and therapeutics for HIV-associated malignancies; 3) investigation of the biology of HIV malignancies within the context of clinical trials; 4) management of issues of international importance in HIV-associated-malignancies; and 5) distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations. The award will provide subcontracts for a coordinating center, core sites, affiliate sites, network laboratories and a statistical center. Sites will receive patient care costs on a capitation basis and for laboratory correlative studies, clinical pharmacology and international studies. The group will have at least four scientific disease-oriented working groups (WG) - KS, lymphoma, HPV-associated cancers, and non-AIDS-Defining Cancers (NADCs) Working Groups .
Mechanism of Support. This FOA will use the NIH U01 cooperative agreement award mechanism.
Funds Available and Anticipated Number of Awards. It is anticipated that $ 4.68 million for year one will be available for this initiative, and one application is expected to be awarded.
